Inventor · disambiguated record
Neil Berinstein
Also filed as: BERINSTEIN NEIL · BERINSTEIN NEIL L
13 granted patents·12 pending applications·43 citations·filing 2000–2021
89Inventor score
Files withBERINSTEIN NEIL11SANOFI PASTEUR LTD7IMMUNOVACCINE TECHNOLOGIES INC4AVENTIS PASTEUR INC1BROOKLYN IMMUNOTHERAPEUTICS LLC1
Top patents by PatentIndex Score
25 records- 0188US8017590B1Method of inducing and/or enhancing an immune response to tumor antigensSANOFI PASTEUR LTD·Filed 2000·Granted Sep 13, 2011·16 cites·31 claims
- 0285US8207314B2Tumor antigens for prevention and/or treatment of cancerBERINSTEIN NEIL·Filed 2004·Granted Jun 26, 2012·15 cites·21 claims
- 0382US10729766B2Method for improving the efficacy of a survivin vaccine in the treatment of cancerIMMUNOVACCINE TECHNOLOGIES INC·Filed 2018·Granted Aug 4, 2020·1 cites·28 claims
- 0475US7851212B2Immunogenic polypeptides encoded by MAGE minigenes and uses thereofSANOFI PASTEUR LTD·Filed 2001·Granted Dec 14, 2010·3 cites·14 claims
- 0572US7851213B2Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancerSANOFI PASTEUR LTD·Filed 2003·Granted Dec 14, 2010·3 cites·32 claims
- 0670US10022441B2Method for improving the efficacy of a survivin vaccine in the treatment of cancerIMMUNOVACCINE TECHNOLOGIES INC·Filed 2013·Granted Jul 17, 2018·1 cites·29 claims
- 0768US8911991B2Multi-antigen vectors of melanomaBERINSTEIN NEIL·Filed 2004·Granted Dec 16, 2014·1 cites·1 claims
- 0866US8021664B2Tumor antigens Bfa5 for prevention and/or treatment of cancerSANOFI PASTEUR LTD·Filed 2004·Granted Sep 20, 2011·3 cites·8 claims
- 0964US2021052724A1Method for improving the efficacy of a survivin vaccine in the treatment of cancerIMMUNOVACCINE TECHNOLOGIES INC·Filed 2020·Application pending·0 cites
- 1062US7790857B2Monoclonal antibodies and uses thereofSANOFI PASTEUR LTD·Filed 2007·Granted Sep 7, 2010·0 cites·29 claims
- 1158US8257717B2Immunogenic polypeptides encoded by MAGE minigenes and uses thereofBERINSTEIN NEIL·Filed 2010·Granted Sep 4, 2012·0 cites·17 claims
- 1258US2010260807A1Methods of Inducing and/or Enhancing an Immune Response To Tumor AntigensBERINSTEIN NEIL·Filed 2009·Application pending·0 cites
- 1357US2023381309A1Methods of treating diffuse large b-cell lymphomaIMMUNOVACCINE TECHNOLOGIES INC·Filed 2021·Application pending·0 cites
- 1457US2011319480A1Method of Inducing and/or Enhancing an Immune Response to Tumor AntigensBERINSTEIN NEIL·Filed 2011·Application pending·0 cites
- 1554US2015352198A1Method of Inducing And/Or Enhancing An Immune Response to Tumor AntigensBERINSTEIN NEIL·Filed 2015·Application pending·0 cites
- 1654US2009156519A1Modified KSA and Uses ThereofAVENTIS PASTEUR INC·Filed 2004·Application pending·0 cites
- 1753US8946174B2Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancerBERINSTEIN NEIL·Filed 2010·Granted Feb 3, 2015·0 cites·24 claims
- 1853US8802383B2Monoclonal antibodies and uses thereofBERINSTEIN NEIL·Filed 2012·Granted Aug 12, 2014·0 cites·20 claims
- 1952US2004223949A1Vaccines using high-dose cytokinesSUNNYBROOK & WOMENS COLLEGE·Filed 2003·Application pending·0 cites
- 2051US8361706B2Monoclonal antibodies and uses thereofSANOFI PASTEUR LTD·Filed 2010·Granted Jan 29, 2013·0 cites·22 claims
- 2150US2013216563A1Immunogenic Polypeptides Encoded by MAGE Minigenes and Uses ThereofBERINSTEIN NEIL·Filed 2012·Application pending·0 cites
- 2248US2013011422A1Tumor Antigens for the Prevention and/or Treatment of CancerBERINSTEIN NEIL·Filed 2012·Application pending·0 cites
- 2347US2016151473A1Vaccines Using High-Dose CytokinesSANOFI PASTEUR LTD·Filed 2016·Application pending·0 cites
- 2442US2020330557A1Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancerBROOKLYN IMMUNOTHERAPEUTICS LLC·Filed 2017·Application pending·0 cites
- 2542US2011311543A1Tumor Antigens BFA5 for Prevention and/or Treatment of CancerBERINSTEIN NEIL·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Neil Berinstein files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →